These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34531086)

  • 21. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
    Lucas CG; Grenert JP; Horvai A
    Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
    Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
    Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
    Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
    Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
    EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Venneker S; Bovée JVMG
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
    Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
    Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of sarcomas by mutant IDH2.
    Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
    Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.
    Schoedel K; Heim T; Duensing A; Lohse I; Presutti L; Belayneh R; Bhogal S; Singh-Varma A; Chang A; Chandran U; Marker D; Szabo-Rogers H; Weiss K
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
    Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
    Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
    Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
    Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
    Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
    Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.